Tanium's Converge World Tour Continues in London
LONDON--(BUSINESS WIRE)--Tanium's Converge World Tour arrives in London today, uniting executives, customers, partners, and product leaders at the Park Plaza, Westminster Bridge.
Attendees will gain insights from Tanium CEO Dan Streetman, who will open the event by addressing the importance of trust and resilience in today's unpredictable threat landscape. Tanium SVP of Product Management, Randy Menon, and Tanium VP of AI, Harman Kaur, will also discuss how Tanium's Autonomous Endpoint Management (AEM) platform empowers organizations to mitigate risk while maintaining operational resiliency.
'Converge World Tour London will showcase how the transformative power of Tanium's AEM platform is helping our customers,' said Steve Hamilton, VP North EMEA. 'This event will provide a unique opportunity for participants to explore cutting-edge innovation and gain valuable insights into enhancing operational security at scale.'
Converge World Tour London highlights include:
Executive panels on 'Why Automation is Step One on your AI Journey' and 'How to Achieve Operation Resilience' featuring Tanium customers and ServiceNow.
Customer panel on 'Automation for Impact and ROI' with speakers from AstraZeneca and other customers.
Tanium Partner Academy, hosted by Tanium SVP, Global Partner Sales, Tony Beller, where the regional winners of the 2025 Partner Awards will be announced.
Hands-on technical labs and breakout sessions including: 'Automating Vulnerability Management,' and 'Maximise Tanium Value with Integrations & APIs' featuring Tanium Senior Directors of Product Management, Julia Grunewald and Shelley Sahani.
For more about an upcoming Converge World Tour event in a city near you, please visit: https://www.tanium.com/converge-world-tour.
About Tanium
Tanium Autonomous Endpoint Management (AEM) offers the most comprehensive solution for intelligently managing endpoints across industries, providing capabilities for asset discovery and inventory, vulnerability management, endpoint management, incident response, risk and compliance, and digital employee experience. The platform supports 34 million endpoints worldwide, including 40% of the Fortune 100, delivering increasingly efficient operations and an improved security posture at scale, with confidence, and in real-time. For more information on The Power of Certainty™, visit www.tanium.com and follow us on LinkedIn and X.
Legal Disclaimer
The information described herein is for general informational purposes only. This information is not a commitment, warranty, offer, promise, or legal obligation for us to deliver any future products, features, or functionality, and is not intended to be, and shall not be deemed to be, incorporated into any contract. The actual timing of any product, feature, or functionality that is ultimately made available may be different from what is described.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
VideoAmp Launches THE REPLAY Revealing New Insights Into Live Sports Audiences
NEW YORK, June 13, 2025--(BUSINESS WIRE)--Today, VideoAmp is debuting a new monthly insights report called THE REPLAY – an interactive analysis of television viewership across major sports tentpole events. Each edition of THE REPLAY will explore the nuances of viewing behavior, regional loyalty, and audience segmentation that shape how America tunes in at home and in public venues leveraging VideoAmp's out-of-home measurement tools. VideoAmp's out-of-home measurement examines whether fans gathered in public venues or stayed home for the big game. Powered by VideoAmp's VALID™ big data and tech engine, THE REPLAY delivers advanced audience ratings and household-level insights in a highly visual and interactive public-facing tool. "For media companies and advertisers alike, THE REPLAY will become a must-use tool for decision-making," said Peter Liguori, Executive Chairman of VideoAmp. "This isn't simply a monthly data dump. Our experts and analysts will be providing an unprecedented and thoughtful look at sports media consumption, and the unique moments when brands can reach passionate, highly engaged viewers that only VideoAmp's advanced audience capabilities make possible." The first edition of THE REPLAY looks back on this year's March Madness, examining how fans watched and where their loyalties shifted. From out-of-home spikes to changing regional dynamics, behavior evolved each round. For example, this month's edition found that during the later rounds of the tournament, the audience included a higher share of top investor households (having at least $100K in invested assets) and those with high discretionary income (HHs $200K). The March 30th Michigan v Auburn game and all the Final Four games including the Championship saw over 1m+ $200k households tune in. The next edition, coming in early July, will highlight the NBA Finals with future months set to explore The Stanley Cup Finals, the NFL season opener and the US Open. In 2024, 75 of the top 100 programs in terms of live audience were sports programming. Streamers know this, and are increasingly investing more in the space. Emarketer recently published a report that projected that over 105 million U.S. viewers watched live sports digitally in 2024, an increase from 95.5 million during the previous year. That same report expects digital viewing of live sports will reach 127.4 million viewers in the U.S., a 21% increase from 2024. About VideoAmp VideoAmp is a media measurement company transforming advertising. By leveraging the power of currency-grade big data, VideoAmp's solutions provide clients with access to advanced audiences and the ability to precisely plan, optimize and measure media investments across platforms to achieve better outcomes. With these solutions, media sellers can increase the value of their inventory, while advertisers can benefit from increased return on investment. VideoAmp has seen incredible adoption for its measurement and currency solutions with 880% YoY growth, 98% coverage of the TV publisher ecosystem, 11 agency groups and more than 1,000+ advertisers. VideoAmp is headquartered in Los Angeles and New York with offices across the United States. To learn more, visit View source version on Contacts Media Contact:Cassady NordeenCassady@ Sign in to access your portfolio
Business Wire
an hour ago
- Business Wire
Valar Labs' CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Valar Labs, a pioneer in AI-powered diagnostics for oncology, announced the publication of its latest research in European Urology, the highest-impact journal in the field of urology. The peer-reviewed study highlights the performance and clinical impact of Valar Labs' Vesta platform in prognosticating outcomes for patients with high grade Ta non muscle invasive bladder cancer, a population frequently on the borderline of guideline-based risk stratification who may receive different treatment depending on which guideline their provider uses. This study demonstrated that CHAI biomarkers can offer improved and additional risk stratification that can go beyond traditional risk factors to better prognosticate outcomes in this population - Dr. Sam S. Chang Bladder cancer treatment remains highly variable in its outcomes, with limited tools available to tailor therapies to individual patients. Valar Labs' Vesta platform, built using advanced artificial intelligence, analyzes pathology to provide critical clinical insights. The newly published study demonstrates that Vesta Risk Stratify biomarkers accurately predicts recurrence and disease progression and outperforms existing guideline-based risk stratification, offering a transformative step forward in precision oncology for bladder cancer. Vesta allows for tailored management based on a patient's individual risk. 'HGTa tumors carry differing risks as current guidelines attempt to address, and clinical factors such as tumor focality and size can help delineate the true nature of these tumors. These clinical factors, however, are somewhat crude and can be misleading at times. This study demonstrated that CHAI biomarkers can offer improved and additional risk stratification that can go beyond traditional risk factors to better prognosticate outcomes in this population.' - Dr. Sam S. Chang, Chief Surgical Officer, Vanderbilt Ingram Cancer Center "The ability to derive clinically meaningful predictive and prognostic information from routinely-collected pathology is a paradigm shift for the risk stratification of bladder cancer patients." - Dr. Siamak Daneshmand, Professor of Urology and Medicine (Oncology), and Director of Urologic Oncology, University of Southern California The multi-center validation study was conducted in collaboration with leading academic centers and underscores both the reproducibility and robustness of the CHAI biomarkers. These findings further establish Vesta as a leading precision oncology platform in the management of non-muscle-invasive bladder cancer. 'This publication is a testament to the clinical significance and scientific rigor of our work,' said Anirudh Joshi, CEO of Valar Labs. 'Vesta's prognostic and predictive tests represent a leap forward in precision medicine for bladder cancer—providing physicians and patients with data-driven insights to guide treatment decisions more effectively.' 'This impactful work continues to build on Vesta's evidence base as the leading predictive and prognostic biomarker portfolio in bladder cancer. We are excited for patients and providers to benefit from this technology,' said Viswesh Krishna, CTO of Valar Labs. Valar Labs continues to expand its suite of AI-driven diagnostic tests under the Vesta portfolio and beyond, aiming to improve outcomes across a range of cancers. For more information or to access the full study, please visit About Valar Labs Valar Labs is a precision medicine company developing computational histology AI diagnostic tests for predicting response to cancer therapies. Our mission is to provide every patient and physician the ability to select the best treatment based on the patient's tumor biology. Vesta is our portfolio of diagnostic tests that predicts which patients are unlikely to benefit from BCG therapy and provides detailed risk stratification for recurrence and progression. Vesta BCGPredict and Vesta Risk Stratify HG are clinically available through our CLIA-certified laboratory in Houston, Texas and can be ordered online. For more information, please visit and follow us on LinkedIn and X.
Business Wire
an hour ago
- Business Wire
KBRA Releases Two Reports on Recurring Revenue Loans' Performance and Trends
NEW YORK--(BUSINESS WIRE)--KBRA releases two research reports that examine the performance of recurring revenue loans (RRL) while also providing an update on the key metrics within RRL securitizations. A breakdown of the two reports is as follows: RRL Performance Review: Private Credit: Recurring Revenue Loans Performance Update reviews the performance of the 189 companies KBRA assessed between 2023 and Q1 2025. We found that private credit lenders have suffered relatively few losses from lending to these high-growth software companies. However, as the strategy matures and underwriting standards evolve, KBRA sought to understand if the relatively low loss rate is sustainable considering the performance of 16% of the population has fallen behind the group. This report details how we arrived at these findings and further explores the RRL landscape. RRL Dashboard: Recurring Revenue Loan Metrics Dashboard: Q1 2025 updates our Q4 analysis that tracks and presents several key metrics in a dashboard format, sourced from quarterly collateral loan tapes provided by the issuers of KBRA-rated RRL asset-backed securities. This update incorporates collateral tapes dated through March 2025 where managers identified eight borrowers that flipped from annual recurring revenue covenants to EBITDA during Q1 2025. Recent Publications Private Credit: Q1 2025 Middle Market Borrower Surveillance Compendium—the Calm Before the Storm Structured Credit Trend Watch: Tariff Uncertainty Clouds Issuance Private Credit: Tariffs and Market Volatility Impact on Private Credit Corporates An Inside Look at Recurring Revenue Loan ABS Private Credit: 2025 Outlook 2025 Structured Credit Sector Outlook: Favorable Currents for Sustained Flow About KBRA KBRA, one of the major credit rating agencies, is registered in the U.S., EU, and the UK. KBRA is recognized as a Qualified Rating Agency in Taiwan, and is also a Designated Rating Organization for structured finance ratings in Canada. As a full-service credit rating agency, investors can use KBRA ratings for regulatory capital purposes in multiple jurisdictions. Doc ID: 1009928
